Remote digital tests to detect and track memory and thinking problems in older adults
Tests a computer and AI platform for tracking memory problems in older adults.
Plain-language title generated from the registry record
Registry title: Remote Digital Assessments for Cognitive Disorders
Key facts
- Where
- Toronto, CanadaSee the site
Where in Canada
- Centre for Addiction and Mental Health (CAMH)Toronto, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre for Addiction and Mental Health
- Trial code
- NCT07883746
- Record updated
- 20 October 2026
- Original description
Memory and thinking problems in older adults, including mild cognitive impairment (MCI) and Alzheimer's disease (AD), can be difficult to assess promptly because evaluation often depends on in-person specialist visits. MonitorCog-AI is a computer-based platform designed to provide a more accessible way to assess and monitor cognitive changes using standard computers or tablets. Artificial intelligence (AI) will be used to analyze the digital information collected by the platform and examine whether combining several types of measures improves assessment of cognitive impairment.Read full original descriptionShow less
A Remote, AI-enabled Multimodal Digital Platform for Timely Detection and Monitoring of Cognitive Disorders: a Study Protocol (MonitorCog-AI)
Memory and thinking problems in older adults, including mild cognitive impairment (MCI) and Alzheimer's disease (AD), can be difficult to assess promptly because evaluation often depends on in-person specialist visits. MonitorCog-AI is a computer-based platform designed to provide a more accessible way to assess and monitor cognitive changes using standard computers or tablets. Artificial intelligence (AI) will be used to analyze the digital information collected by the platform and examine whether combining several types of measures improves assessment of cognitive impairment.
The study will include 60 adults aged 50 years and older: 20 healthy adults, 20 adults with MCI, and 20 adults with AD. Participants will be assessed at baseline, 6 months, and 12 months. At each timepoint, participants will complete one clinical assessment and one digital assessment. The clinical assessment will include standard measures of memory and thinking, an assessment of daily functioning, and a brief recording of brain electrical activity. The digital assessment will take approximately 60-80 minutes and will assess five areas: cognition, eye movements measured using a webcam, language, speech, and fine-motor performance measured using a mouse. At baseline, the digital assessment will be completed in the clinic; at 6 and 12 months, it will usually be completed remotely at home.
The study has three main goals. First, it will determine whether MonitorCog-AI is feasible, acceptable, easy to use, and not overly burdensome for repeated assessment. Second, it will examine how well AI-based analysis of the digital measures distinguishes healthy adults, adults with MCI, and adults with AD, and whether combining several types of digital information performs better than any single type alone. Third, it will examine how digital measures change over 12 months and whether these changes are related to changes in clinical measures of cognition and daily functioning.
Inclusion: Age 50 years or older; Sufficient English literacy to complete study assessments; Capacity to provide informed consent; Ability to attend in-person study assessments; Healthy controls: Montreal Cognitive Assessment (MoCA) score >26 and no history of a DSM-5 neurocognitive disorder; Mild cognitive impairment (MCI) group: meets DSM-5 criteria for mild neurocognitive disorder based on clinical adjudication; Alzheimer's disease (AD) group: meets DSM-5 criteria for major neurocognitive disorder due to AD based on clinical adjudication.
Exclusion: Recent psychotropic medication changes likely to affect cognition; Major psychiatric, neurological, or unstable medical condition that may interfere with study participation; Current or recent substance-use disorder; Uncorrectable visual impairment that would interfere with computerized assessment; Motor impairment preventing use of a mouse or touchpad; Participation in a conflicting interventional clinical trial.